Periodic Reporting for period 1 - BRIGHT (40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease)
Reporting period: 2019-05-01 to 2019-09-30
BRIGHT aims to develop 40 Hz flickering light therapy using novel invisible spectral flicker (ISF) that can induce brainwaves in AD patients and potentially improve cognition and potentially slow the disease progression. The light is combined in a way that the flickering is non-perceptible and thus not hindering vision or causing discomfort. The primary objective of the project is to validate the need for such a treatment, and establish the necessary partners for the clinical evaluation.
- User requirements addressed by subsequent new design features
- Market analysis that identified the most interesting market segment, in regards to effect, willingness and size. This sharpens our eye and approach onwards in regards to product development, strategy and IPR
- Effective and detailed national go-to-market strategy and business model to address the market segment, including supply and sales setup
- Strong partnership with key clinical partners and pilot test participants
Furthermore a clear plan of the implementations of the 40 Hz neuromodulation light in a business setting is prepared - Ultimately leading to potentially better health and life among the population.